Alec Stranahan
Stock Analyst at B of A Securities
(0.61)
# 3,867
Out of 4,870 analysts
31
Total ratings
33.33%
Success rate
-31.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $16.71 | +151.35% | 1 | Mar 28, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Neutral | $14 → $12 | $4.72 | +154.24% | 5 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Buy | $15 | $4.67 | +221.20% | 1 | Feb 7, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $6.48 | +285.80% | 4 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.32 | +733.33% | 1 | Jan 7, 2025 | |
| ERAS Erasca | Upgrades: Buy | $5 | $1.39 | +259.71% | 2 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $4.11 | +45.99% | 2 | Nov 25, 2024 | |
| EDIT Editas Medicine | Upgrades: Buy | $13 → $15 | $2.10 | +614.29% | 1 | Aug 8, 2024 | |
| RVMD Revolution Medicines | Maintains: Buy | $48 → $55 | $40.04 | +37.36% | 3 | Jul 16, 2024 | |
| NVAX Novavax | Maintains: Neutral | $12 → $18 | $6.31 | +185.26% | 3 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $140 | $137.95 | +1.49% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $8.40 | +400.00% | 1 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $36.56 | -83.59% | 2 | Dec 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $60 → $5 | $1.27 | +293.70% | 1 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $46.97 | -4.18% | 1 | Dec 1, 2022 |
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $16.71
Upside: +151.35%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $4.72
Upside: +154.24%
Candel Therapeutics
Feb 7, 2025
Initiates: Buy
Price Target: $15
Current: $4.67
Upside: +221.20%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $6.48
Upside: +285.80%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.32
Upside: +733.33%
Erasca
Jan 7, 2025
Upgrades: Buy
Price Target: $5
Current: $1.39
Upside: +259.71%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $4.11
Upside: +45.99%
Editas Medicine
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.10
Upside: +614.29%
Revolution Medicines
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $40.04
Upside: +37.36%
Novavax
Jun 14, 2024
Maintains: Neutral
Price Target: $12 → $18
Current: $6.31
Upside: +185.26%
May 25, 2023
Maintains: Buy
Price Target: $118 → $140
Current: $137.95
Upside: +1.49%
May 19, 2023
Initiates: Buy
Price Target: $42
Current: $8.40
Upside: +400.00%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $36.56
Upside: -83.59%
Dec 2, 2022
Downgrades: Underperform
Price Target: $60 → $5
Current: $1.27
Upside: +293.70%
Dec 1, 2022
Initiates: Buy
Price Target: $45
Current: $46.97
Upside: -4.18%